Literature DB >> 23282201

Bone marrow transplantation in hindlimb muscles of motoneuron degenerative mice reduces neuronal death and improves motor function.

Diego Pastor1, Mari Carmen Viso-León, Arancha Botella-López, Jesus Jaramillo-Merchan, Jose M Moraleda, Jonathan Jones, Salvador Martínez.   

Abstract

Bone marrow has proved to be an adequate source of stem cells for the treatment of numerous disorders, including neurodegenerative diseases. Bone marrow can be easily and relatively painlessly extracted from a patient or allogenic donor and then transplanted into the degenerative area. Here, the grafted cells will activate a number of mechanisms in order to protect, repair, and/or regenerate the damaged tissue. These properties make the bone marrow a feasible source for cell therapy. In this work, we transplanted bone marrow cells into a mouse model of motoneuron degeneration, with the particularity of placing the cells in the hindlimb muscles rather than in the spinal cord where neuronal degeneration occurs. To this end, we analyze the possibility for the transplanted cells to increase the survival rate of the spinal cord motoneurons by axonal-guided retrograde neurotrophism. As a result, the mice significantly improved their motor functions. This coincided with an increased number of motoneurons innervating the treated muscle compared with the neurons innervating the non-treated contralateral symmetric muscle. In addition, we detected an increase in glial-derived neurotrophic factor in the spinal cord, a neurotrophic factor known to be involved in the rescue of degenerating motoneurons, exerting a neuroprotective effect. Thus, we have proved that bone marrow injected into the muscles is capable of rescuing these motoneurons from death, which may be a possible therapeutic approach for spinal cord motoneuron degenerative diseases, such as amyotrophic lateral sclerosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23282201      PMCID: PMC3657290          DOI: 10.1089/scd.2012.0487

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  52 in total

1.  Quantitative assessment of neurologic deficits in a chronic progressive murine model of CNS demyelination.

Authors:  D B McGavern; L Zoecklein; K M Drescher; M Rodriguez
Journal:  Exp Neurol       Date:  1999-07       Impact factor: 5.330

2.  FGF-9 is an autocrine/paracrine neurotrophic substance for spinal motoneurons.

Authors:  T Kanda; T Iwasaki; S Nakamura; A Ueki; T Kurokawa; K Ikeda; H Mizusawa
Journal:  Int J Dev Neurosci       Date:  1999-06       Impact factor: 2.457

3.  Differential effects of neurotrophic factors on motoneuron retrograde labeling in a murine model of motoneuron disease.

Authors:  Y Sagot; T Rossé; R Vejsada; D Perrelet; A C Kato
Journal:  J Neurosci       Date:  1998-02-01       Impact factor: 6.167

4.  A high-resolution genetic map of mouse chromosome 19 encompassing the muscle-deficient osteochondrodystrophy (mdf-ocd) region.

Authors:  C Poirier; S Blot; M Fernandes; G F Carle; V Stanescu; R Stanescu; J L Guénet
Journal:  Mamm Genome       Date:  1998-05       Impact factor: 2.957

5.  'Green mice' as a source of ubiquitous green cells.

Authors:  M Okabe; M Ikawa; K Kominami; T Nakanishi; Y Nishimune
Journal:  FEBS Lett       Date:  1997-05-05       Impact factor: 4.124

6.  Increased expression of glial cell line-derived neurotrophic factor mRNA in muscle biopsies from patients with amyotrophic lateral sclerosis.

Authors:  E Grundström; H Askmark; J Lindeberg; I Nygren; T Ebendal; S M Aquilonius
Journal:  J Neurol Sci       Date:  1999-01-15       Impact factor: 3.181

7.  Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors.

Authors:  G Haase; P Kennel; B Pettmann; E Vigne; S Akli; F Revah; H Schmalbruch; A Kahn
Journal:  Nat Med       Date:  1997-04       Impact factor: 53.440

8.  Therapeutic benefit of ciliary neurotrophic factor in progressive motor neuronopathy depends on the route of delivery.

Authors:  G Haase; B Pettmann; T Bordet; P Villa; E Vigne; H Schmalbruch; A Kahn
Journal:  Ann Neurol       Date:  1999-03       Impact factor: 10.422

9.  GDNF expression is increased in denervated human skeletal muscle.

Authors:  D C Lie; J Weis
Journal:  Neurosci Lett       Date:  1998-07-03       Impact factor: 3.046

10.  Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS.

Authors:  E D Hall; J A Oostveen; M E Gurney
Journal:  Glia       Date:  1998-07       Impact factor: 7.452

View more
  10 in total

Review 1.  Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Stephen A Goutman; Kevin S Chen; Eva L Feldman
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

2.  Bone marrow transplantation in dysferlin-deficient mice results in a mild functional improvement.

Authors:  Bàrbara Flix; Xavier Suárez-Calvet; Jordi Díaz-Manera; Eva Santos-Nogueira; Renzo Mancuso; Jordi Barquinero; Miquel Navas; Xavier Navarro; Isabel Illa; Eduard Gallardo
Journal:  Stem Cells Dev       Date:  2013-07-26       Impact factor: 3.272

3.  Mesenchymal stem cells improve motor functions and decrease neurodegeneration in ataxic mice.

Authors:  Jonathan Jones; Alicia Estirado; Carolina Redondo; Jesus Pacheco-Torres; Maria-Salomé Sirerol-Piquer; José M Garcia-Verdugo; Salvador Martinez
Journal:  Mol Ther       Date:  2014-07-29       Impact factor: 11.454

4.  Safety and Biodistribution of Human Bone Marrow-Derived Mesenchymal Stromal Cells Injected Intrathecally in Non-Obese Diabetic Severe Combined Immunodeficiency Mice: Preclinical Study.

Authors:  Mari Paz Quesada; David García-Bernal; Diego Pastor; Alicia Estirado; Miguel Blanquer; Ana Mª García-Hernández; José M Moraleda; Salvador Martínez
Journal:  Tissue Eng Regen Med       Date:  2019-07-26       Impact factor: 4.169

5.  Intramuscular transplantation of bone marrow cells prolongs the lifespan of SOD1G93A mice and modulates expression of prognosis biomarkers of the disease.

Authors:  Amaya Rando; Diego Pastor; Mari Carmen Viso-León; Anna Martínez; Raquel Manzano; Xavier Navarro; Rosario Osta; Salvador Martínez
Journal:  Stem Cell Res Ther       Date:  2018-04-06       Impact factor: 6.832

6.  Early electrical field stimulation prevents the loss of spinal cord anterior horn motoneurons and muscle atrophy following spinal cord injury.

Authors:  Cheng Zhang; Wei Rong; Guang-Hao Zhang; Ai-Hua Wang; Chang-Zhe Wu; Xiao-Lin Huo
Journal:  Neural Regen Res       Date:  2018-05       Impact factor: 5.135

Review 7.  Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates.

Authors:  Flore Gouel; Anne-Sophie Rolland; Jean-Christophe Devedjian; Thierry Burnouf; David Devos
Journal:  Front Neurol       Date:  2019-08-02       Impact factor: 4.003

8.  Combined intramuscular and intraspinal transplant of bone marrow cells improves neuromuscular function in the SOD1G93A mice.

Authors:  Anna Martínez-Muriana; Diego Pastor; Renzo Mancuso; Amaya Rando; Rosario Osta; Salvador Martínez; Rubèn López-Vales; Xavier Navarro
Journal:  Stem Cell Res Ther       Date:  2020-02-07       Impact factor: 6.832

9.  Autologous bone marrow mononuclear cells as neuroprotective treatment of amyotrophic lateral sclerosis.

Authors:  Francisco José Ruiz-López; Miguel Blanquer
Journal:  Neural Regen Res       Date:  2016-04       Impact factor: 5.135

10.  Intramuscular Injection of Bone Marrow Stem Cells in Amyotrophic Lateral Sclerosis Patients: A Randomized Clinical Trial.

Authors:  Emilio Geijo-Barrientos; Carlos Pastore-Olmedo; Pedro De Mingo; Miguel Blanquer; Joaquín Gómez Espuch; Francisca Iniesta; Natalia García Iniesta; Ana García-Hernández; Carlos Martín-Estefanía; Laura Barrios; José M Moraleda; Salvador Martínez
Journal:  Front Neurosci       Date:  2020-03-24       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.